Rituximab can induce remission of nephrotic syndrome in the absence of peripheral B-cells

Nephrology (Carlton). 2015 Sep;20(9):667-8. doi: 10.1111/nep.12492.

Authors

Ilse M Rood¹, Job Huussen², Jack F Wetzels¹, Jeroen K Deegens¹

Affiliations

¹ Department of Nephrology, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
² Department of Internal Medicine, Slingeland Hospital, Doetinchem, The Netherlands.

PMID: 26278122
DOI: 10.1111/nep.12492

No abstract available

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Aged
B-Lymphocytes / drug effects*
B-Lymphocytes / immunology
Female
Humans
Immunosuppressive Agents / therapeutic use*
Nephrotic Syndrome / diagnosis
Nephrotic Syndrome / drug therapy*
Nephrotic Syndrome / immunology
Remission Induction
Rituximab / therapeutic use*
Treatment Outcome

Substances

Immunosuppressive Agents
Rituximab